Analytical Data
-
Gene name
IGFBP4
- Application
-
Alternative Names
IGFBP4；IBP4；Insulin-like growth factor-binding Protein 4
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P22692
-
Expression Region
22-258aa
-
AA Sequence
DEAIHCPPCSEEKLARCRPPVGCEELVREPGCGCCATCALGLGMPCGVYT PRCGSGLRCY PPRGVEKPLHTLMHGQGVCMELAEIEAIQESLQPSDKDEGDHPNNSFSPC SAHDRRCLQK HFAKIRDRSTSGGKMKVNGAPREDARPVPQGSCQSELHRALERLAASQSR THEDLYIIPI PNCDRNGNFHPKQCHPALDGQRGKCWCVDRKTGVKLPGGLEPKGELDCHQ LADSFREVDHHHHHH
-
Molecular Weight
27 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IGFBP4 (Insulin-like Growth Factor Binding Protein 4) is a member of the IGFBP family, which plays a crucial role in the regulation of insulin-like growth factors (IGFs). These proteins are vital for cell growth, proliferation, and differentiation, making IGFBP4 particularly significant in various physiological and pathological processes, including cancer progression, development, and metabolic disorders. Research has shown that IGFBP4 not only modulates IGF activity by prolonging its half-life and facilitating its transport to target cells but also exhibits IGF-independent functions that influence cellular signaling pathways. Additionally, alterations in IGFBP4 expression levels have been linked to various diseases, including obesity, diabetes, and certain cancers, highlighting its potential as a biomarker and therapeutic target. The production of recombinant IGFBP4 protein allows for detailed studies of its functional roles and mechanisms of action in signaling pathways. By utilizing recombinant DNA technology, researchers can generate a high-yield, purified form of IGFBP4, paving the way for in-depth investigations into its structure-function relationships and interactions with IGFs and other molecules. This research is poised to enhance our understanding of IGFBP4's contributions to health and disease, potentially leading to novel therapeutic strategies for conditions where IGFBP4 dysregulation is implicated.
